Benefits of cardiac resynchronization therapy in "very dilated cardiomyopathy"

Ana Lousinha1, Mário M Oliveira, Joana Feliciano

  • 1Serviço de Cardiologia, Hospital de Santa Marta, Lisboa, Portugal. lousinha@hotmail.com

Insights

Patients with very dilated cardiomyopathy showed a higher clinical response rate to cardiac resynchronization therapy (CRT). However, reverse remodeling was similar across groups, indicating LVEDD may not solely predict CRT success.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is used for advanced heart failure.
  • Left ventricular end-diastolic dimension (LVEDD) is a potential predictor of CRT response.

Purpose of the Study:

  • To investigate CRT response in patients with very dilated cardiomyopathy (LVEDD ≥ 45 mm/m²).
  • To compare responder rates and reverse remodeling between patients with very dilated cardiomyopathy and those with less dilated ventricles (37 mm/m² < LVEDD < 45 mm/m²).

Main Methods:

  • Retrospective analysis of 71 heart failure patients undergoing CRT.
  • Patients were divided into two groups based on LVEDD: Group A (very dilated) and Group B.
  • Echocardiography assessed NYHA class, LVEF, and LVEDD at baseline and 6 months post-CRT.

Main Results:

  • Overall, 79% of patients were clinical responders with improved LVEF and reduced LVEDD.
  • Very dilated cardiomyopathy patients (Group A) showed a significantly higher clinical responder rate (96% vs. 72%).
  • Reverse remodeling, LVEF improvement, and LVEDD reduction were similar between groups.

Conclusions:

  • A significant number of patients achieve reverse remodeling after CRT.
  • While very dilated cardiomyopathy patients exhibit better functional class improvement, the degree of reverse remodeling is comparable across LVEDD groups.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...